Browse > Article
http://dx.doi.org/10.5352/JLS.2010.20.5.799

Association Study between Genetic Polymorphisms of CYP2C19 Gene and Essential Hypertension in Koreans  

Park, Ah-Ram (Cardiovascular Genome Center, Yonsei University College of Medicine)
Shin, Eun-Soon (DNA Link Inc.)
Son, Nak-Hoon (Cardiovascular Genome Center, Yonsei University College of Medicine)
Jang, Yang-Soo (Cardiovascular Genome Center, Yonsei University College of Medicine)
Shin, Dong-Jik (Cardiovascular Genome Center, Yonsei University College of Medicine)
Publication Information
Journal of Life Science / v.20, no.5, 2010 , pp. 799-804 More about this Journal
Abstract
In humans, CYP2C19, a member of the cytochrome P450 subfamily, metabolizes arachidonic acid to produce epoxyicosanoid acids, which are involved in vascular tone and regulation of blood pressure (BP). Recent findings suggest that CYP2C19 gene polymorphisms might be considered as a novel candidate gene for cardiovascular disease. We thus focused on the Korean population to explore the association of two polymorphisms ($CYP2C19^*2$ and $^*3$) in this gene and essential hypertension (EH). A total of 1,241 participants (537 hypertensive subjects and 704 healthy controls) were recruited from the Yonsei Cardiovascular Genome Center in Korea. The CYP2C19 polymorphisms were genotyped using the $SNaPShot^{TM}$ assay. The allele and genotype frequencies of $CYP2C19^*3$ showed significant difference between hypertensives and normotensives (P=0.019 and P=0.023, respectively). Logistic regression analysis indicated that the $CYP2C19^*3$ A allele carriers were significantly associated with EH (OR, 0.723; 95% CI, 0.538-0.972, P=0.032) under a dominant model. In addition, CYP2C19 G-A haplotype ($2C19^*2\;G-^*3$ A combination) was found to significantly reduce EH risk (OR, 0.714, P=0.015). We believe this provides evidence that $CYP2C19^*3$ polymorphism may contribute to a protective effect in the development of EH.
Keywords
Hypertension; CYP2C19; polymorphism; haplotype; association;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Goldstein, J. A., T. Ishizaki, K. Chiba, S. M. de Morais, D. Bell, P. M. Krahn, and D. A. Evans. 1997. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7, 59-64.   DOI   ScienceOn
2 Gray, I. C., C. Nobile, R. Muresu, S. Ford, and N. K. Spurr. 1995. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 28, 328-332.   DOI   ScienceOn
3 Harrap, S. B. 1994. Hypertension: genes versus environment. Lancet 344, 169-171.   DOI   ScienceOn
4 Herrlin, K., A. Y. Massele, M. Jande, C. Alm, G. Tybring, Y. A. Abdi, A. Wennerholm, I. Johansson, M. L. Dahl, L. Bertilsson, and L. L. Gustafsson. 1998. Bantu Tanzanians have a decreased capacity to metablolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin. Pharmacol. Ther. 64, 391-401.   DOI   ScienceOn
5 Aynacioglu, A. S., C. Sachse, A. Bozkurt, S. Kortunay, M. Nacak, T. Schroder, S. O. Kayaalp, I. Roots, and J. Brockmoller. 1999. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin. Pharmacol. Ther. 48, 409-415.
6 Bae, Y., C. Park, J. Han, Y. J. Hong, H. H. Song, E. S. Shin, J. E. Lee, B. G. Han, Y. Jang, D. J. Shin, and S. K. Yoon. 2007. Interaction between GNB3 C825T and ACE I/D polymorphisms in essential hypertension in Koreans. J. Hum. Hypertens. 21, 159-166.   DOI   ScienceOn
7 Bertrand-Thiebault, C., H. Berrahmoune, A. Thompson, B. Marie, S. Droesch, G. Siest, D. Foernzler, and S. Visvikis-Siest. 2008. Genetic polymorphisms of CYP2C19 gene in the Stanislas Cohort. A link with inflammation. Ann. Hum. Genet. 72, 178-183.   DOI   ScienceOn
8 Chen, L., S. Qin, J. Xie, J. Tang, L. Yang, W. Shen, X. Zhao, J. Du, G. He, G. Feng, L. He, and Q. Xing. 2008. Genetic polymorphisms analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 9, 691-702.   DOI   ScienceOn
9 Yamada, S., M. Onda, S. Kato, N. Matsuda, T. Matsuhisa, N. Yamada, M. Miki, and N. Matsukura. 2001. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J. Gastroenterol. 36, 696-699.   DOI   ScienceOn
10 Xie, H. G., C. M. Stein, R. B. Kim, G. R. Wilkinson, D. A. Flockhart, and A. J. Wood. 1999. Allelic, genotypic distributions of S-mephenytoin 4’-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9, 539-549.   DOI   ScienceOn
11 Zand, N., N. Tajik, A. S. Moghaddam, and I. Milanian. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin. Exp. Pharmacol. Physiol. 34, 2-5.
12 Rahman, M., J. T. Wright, and J. G. Douglas. 1997. The role of cytochrome P450 dependent metabolites of arachidonic acid in blood pressure regulation and renal function. Am. J. Hypertens. 10, 356-365.   DOI   ScienceOn
13 Lee, S. S., S. J. Lee, J. Gwak, H. J. Jung, H. Thi-Le, I. S. Song, E. Y. Kim, and J. G. Shin. 2007. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther. Drug Monit. 29, 455-459.   DOI   ScienceOn
14 Lee, J. M., S. H. Park, D. J. Shin, D. H. Choi, C. Y. Shim, Y. G. Ko, J. S. Kim, E. S. Shin, C. W. Chang, J. E. Lee, and Y. S. Jang. 2009. Relation of genetic polymorphisms in the cytochrome P450 gene with Clopidogrel resistance after drug-eluting stent implantation in Koreans. Am. J. Cardiol. 104, 46-51.   DOI   ScienceOn
15 Ozawa, S., A. Soyama, M. Saeki, H. Fukushima-Uesaka, M. Itoda, S. Koyano, Y. Ohno, Y. Saito, and J. Sawada. 2004. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokinet. 17, 150-156.
16 Roh, H. K., M. L. Dahl, G. Tybring, H. Yamada, Y. N. Cha, and L. Bertilsson. 1996. Debrisoquine and S- mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 6, 441-447.   DOI   ScienceOn
17 Scordo, M. G., A. P. Caputi, C. D’Arrigo, G. Fava, and E. Spina. 2004. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol. Res. 50, 195-200.   DOI   ScienceOn
18 Turner, S. T., E. Boerwinkle, and C. F. Sing. 1999. Context-dependent associations of the ACE I/D polymorphism with blood pressure. Hypertension 34, 773-778.   DOI
19 Taguchi, M., T. Nozawa, K. Mizumaki, H. Inoue, K. Tahara, C. Takesono, and Y. Hashimoto. 2004. Nonlinear mixed effects model analysis of the pharmacokinitics of metoprolol in routinely treated Japanese patients. Biol. Pharm. Bull. 27, 1642-1648.   DOI   ScienceOn
20 Tassaneeyakul, W., W. Mahatthanatrakul, K. Niwatananun, K. Na-Bangchang, A. Tawalee, N. Krikreangsak, U. Cykleng, and W. Tassaneeyakul. 2006. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab. Pharmacokinet. 21, 286-290.   DOI   ScienceOn
21 De Morais, S. M., G. R. Wilkinson, J. Blaisdell, U. A. Meyer, K. Nakamura, and J. A. Goldstein. 1994. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46, 594-598.
22 De Morais, S. M., G. R. Wilkinson, J. Blaisdell, K. Nakamura, U. A. Meyer, and J. A. Goldstein. 1994. The major genetic defect responsible for the polymorphism S-mephenytoin metabolism in humans. J. Biol. Chem. 269, 15419-15422.
23 Friedewald, W. T., R. I. Levy, and D. S. Fredrickson. 1972. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499-502.
24 Fukushima-Uesaka, H., Y. Saito, K. Maekawa, S. Ozawa, R. Hasegawa, H. Kajio, N. Kuzuya, K. Yasuda, M. Kawamoto, N. Kamatani, K. Suzuki, T. Yanagawa, M. Tohkin, and J. I. Sawada. 2005. Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab. Pharmacokinet. 20, 300-307.   DOI   ScienceOn
25 Goldstein, J. A. 2001. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52, 349-355.   DOI   ScienceOn